U.S. Government Ramps Up Alzheimer’s Research

September 6, 2018

On August 23rd the U.S. Senate voted to pass the largest increase in history earmarked for Alzheimer’s Research. The increase of $425 million would go to Alzheimer’s and dementia research funding at the National Institutes of Health. This funding would bring the country’s total investment to $2.34 billion for fiscal year 2019. If signed into law, this would mark the fourth year in a row that the United States Congress has addressed the growing Alzheimer’s crisis through funding research.

We know the numbers by now, but to recap: more than five million Americans are living with Alzheimer’s, the most expensive disease in the country. What was once misunderstand as “old-timers disease” is now a known and growing public health crisis in this country. Threatening to bankrupt Medicare, it’s projected that as many as 14 million Americans could be living with Alzheimer’s by 2050.

“Every 65 seconds someone in the U.S. develops the disease,” said Harry Johns, Alzheimer’s Association and Alzheimer’s Impact Movement (AIM) President and CEO. “But, thanks to increased NIH funding, American scientists are now advancing basic disease knowledge, ways to reduce risk, new biomarkers for early diagnosis and drug targeting, and developing the needed treatments to move to clinical testing.”

Once the legislation is approved by a conference committee and signed into law, this amount will surpass the $2 billion per year experts have said is needed to prevent and treat Alzheimer’s by the year 2025.

If you enjoyed reading this blog on the latest Alzheimer’s news, check out some of our other blogs discussing the science of dementia HERE.

Source

Other Articles

  • Breakthrough: Blood Test Makes it Possible to Track Alzheimer’s Advancement 
    A connection between Neurofilament light (NfL) levels present in the blood and Alzheimer’s disease was recently made in a study released by the JAMA Network.
  • New Study Might Diagnose CTE in Brains of the Living
    A recent study published in the New England Journal of medicine revealed that brain scans of more than two dozen former NFL players found that the men had abnormal levels of the protein linked to chronic traumatic encephalopathy (C.T.E.), the degenerative brain disease we have discussed here that’s associated with repeated hits to the head.  
  • JUST PUT DOWN THE SUPPLEMENTS 
    There have long been debates among established medical authorities and supplement manufacturers, especially when it comes to treating cognitive decline. Are the myriad of supplements currently on the market a genie in a bottle? Or is it better to focus on leading a healthy, balanced lifestyle? 
  • BREAKING NEWS: Promising Alzheimer’s Drug Fails in Late-Stage Human Trials 
    Another big blow came to the Alzheimer’s research community late last month when pharmaceutical company Biogen and Eisai Co. announced on March 22 that they would terminate two late-stage studies of
  • Could a Noninvasive Eye Exam Preemptively Diagnose Alzheimer’s Disease? 
    That’s what a recent study conducted at the Duke Eye Center suggests. The study of more than 200 people, published on March 11 in the journal Ophthalmology Retina, proposes that a quick, noninvasive
  • Tom Seaver Diagnosis Reignites Lyme Disease & Dementia Debate
    AN ARTICLE IN The New York Times recently revealed that Tom Seaver, legendary pitcher and the most prominent player in New York Mets history, is stepping back from public life because of advancing dementia. It was recently discovered that Seaver, 74, has dementia. However, for many years he suffered from the effects of Lyme disease, which can cause cognitive problems similar to dementia.